RxDoctor Payments Data

David George, MD

Hematology & Oncology · Bastrop, TXNPI 1164465563

Payments from drug & device makers

$497in general payments, 2019–2025

Across 19 payments — averaging $26.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$164
  • Incyte Corporation$85
  • GSK$59
  • Jazz Pharmaceuticals Inc.$46
  • Bristol Myers Squibb$29
  • Tempus AI, Inc$24
  • plus $90 from 5 others

What the payments were for

  • Food & beverage$31964%
  • Education$17936%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$497 in reported general payments places this provider in the 15th percentile of 838 hematology & oncology providers in Texas.

See all hematology & oncology providers in Texas

Medicare billing

Part B allowed, 2024
$2,432,879
Medicare patients
506
Services billed
136,582

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide14$329,401
CabometyxCabozantinib S-Malate12$283,008
XalkoriCrizotinib12$243,767
RevlimidLenalidomide13$236,067
VenclextaVenetoclax28$214,929
KisqaliRibociclib Succinate11$176,206
XtandiEnzalutamide11$154,877
CalquenceAcalabrutinib Maleate12$147,830
EliquisApixaban58$52,911
XareltoRivaroxaban53$44,173
OxycontinOxycodone Hcl15$7,605
Exemestane32$4,802
ValacyclovirValacyclovir Hcl49$2,995
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen68$2,194
Fentanyl29$1,899

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$22$329,40114 claims
Bristol Myers SquibbRevlimid$29$236,06713 claims
NovartisKisqali$17$176,20611 claims
Johnson & JohnsonXarelto$164$44,17353 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 838 hematology & oncology providers in Texas.

Other hematology & oncology in Bastrop

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →